biib - Search News

US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday.

Seeking Alpha on MSN · 30m

Biogen, Eisai Alzheimer’s drug review delayed in EU

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the region's drug regulator to reconsider a prior decision that endorsed the anti-amyloid therapy.

Business Insider · 4d

FDA Approves Once-Every-Four-Weeks Maintenance Dosing Of LEQEMBI For Early Alzheimer's Disease

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced Sunday that the U.S. Food and Drug Administration has approved the

Zacks.com on MSN · 3d

BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug

Biogen BIIB announced that the FDA has approved a monthly maintenance dosing version for its intravenously (IV) administered Alzheimer's disease (AD) drug, Leqembi. Post the FDA approval, patients have the option to transition to a monthly maintenance dosing regimen of Leqembi after completing an 18-month course of biweekly infusions of the drug.

Biogen Inc. (NASDAQ:BIIB) Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp reduced its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.4% in the fourth quarter, ...

Zacks.com on MSN1d

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Biogen provides update on EU regulatory review of lecanemab in Alzheimer’s

Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...

Exchange Traded Concepts LLC Boosts Position in Biogen Inc. (NASDAQ:BIIB)

Exchange Traded Concepts LLC lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.5% during the 4th ...

SAGE Stock Up on Rejecting BIIB’s Proposal

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...

22h

Biogen (BIIB) Gets a Hold from Piper Sandler

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

24/7 Wall St. on MSN9d

Billionaire Sells Palantir Stock and Buys This Stock That Could Soar 64% According to a Wall Street Expert

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Zacks.com on MSN19h

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

Breaking Down Biogen: 18 Analysts Share Their Views

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

news.stocktradersdaily8d

Learn to Evaluate (BIIB) using the Charts

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB. Type a few ...

Biogen (BIIB) Gets a Buy from RBC Capital

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics